SCOPUS 정보 검색 플랫폼

Volumn 18, Issue 4, 2016, Pages 425-429

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine

(6) Hadjiyianni, I a Dahl, D b Lacaya, L B c Pollom, R K c Chang, C L c,d Ilag, L L c

a LILLY DEUTSCHLAND GMBH (Germany)

b Gründungsvorsitzender der Arbeitsgemeinschaft Diabetes und Migranten (Germany)

c ELI LILLY AND COMPANY (United States)

d CHIA YI CHRISTIAN HOSPITAL (Taiwan)

Author keywords

Biosimilar insulin; Insulin glargine; LY2963016 insulin glargine

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ANTIBODY; INSULIN GLARGINE; ANTIDIABETIC AGENT; BIOSIMILAR AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LY2963016 INSULIN GLARGINE;

ALLERGY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT-EMERGENT ANTIBODY RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HYPERGLYCEMIA; HYPOGLYCEMIA;

BIOSIMILAR PHARMACEUTICALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE;

EID: 84959919994 PISSN: 14628902 EISSN: 14631326 Source Type: Journal
DOI: 10.1111/dom.12628 Document Type: Article

Times cited : (23)

References (15)

1
- 84959892688
- European Medicines Agency. Lantus. . Available from URL:. Accessed 18 May 2015.
- European Medicines Agency. Lantus. 2015. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000284/human_med_000882.jsp&mid=WC0b01ac058001d124. Accessed 18 May 2015.
- (2015)

2
- 84902264578
- The evolution of insulin glargine and its continuing contribution to diabetes care
- Hilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 2014; 74: 911-927.
- (2014) Drugs , vol.74 , pp. 911-927
- Hilgenfeld, R.¹ Seipke, G.² Berchtold, H.³ Owens, D.R.⁴

3
- 84959919964
- Eli Lilly and Company Press Release. European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe. . Available from URL:. Accessed 18 May 2015.
- Eli Lilly and Company Press Release. European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe. 2014. Available from URL: http://lilly.mediaroom.com/index.php?s=9042&item=137348. Accessed 18 May 2015.
- (2014)

4
- 84959893317
- Pharmaceuticals and Medical Devices Agency. New drugs approved in FY . Available from URL:. Accessed 10 December 2015.
- Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2014. Available from URL: http://www.pmda.go.jp/files/000206818.pdf. Accessed 10 December 2015.
- (2014)

5
- 84959898396
- European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). . Available from URL:. Accessed 16 June 2015.
- European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf. Accessed 16 June 2015.
- (2012)

6
- 84959918484
- European Medicines Agency. Abasaglar (formerly Abrasria). . Available from URL:. Accessed 18 May 2015.
- European Medicines Agency. Abasaglar (formerly Abrasria). 2015. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002835/human_med_001790.jsp&mid=WC0b01ac058001d124. Accessed 18 May 2015.
- (2015)

7
- 84962360228
- Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies
- Linnebjerg H, Lam EC, Seger ME et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care 2015; 38: 2226-2233.
- (2015) Diabetes Care , vol.38 , pp. 2226-2233
- Linnebjerg, H.¹ Lam, E.C.² Seger, M.E.³

8
- 84937816371
- ®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
- ®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab 2015; 17: 726-733.
- (2015) Diabetes Obes Metab , vol.17 , pp. 726-733
- Blevins, T.C.¹ Dahl, D.² Rosenstock, J.³

9
- 84937817049
- ®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
- ®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 2015; 17: 734-741.
- (2015) Diabetes Obes Metab , vol.17 , pp. 734-741
- Rosenstock, J.¹ Hollander, P.² Bhargava, A.³

10
- 0031578033
- Recommendations guiding physicians in biomedical research involving human subjects
- World Medical Association Declaration of Helsinki. . ; : -.
- World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
- (1997) JAMA , vol.277 , pp. 925-926

11
- 84956873259
- ® insulin glargine in patients with type 1 diabetes mellitus or type 2 diabetes mellitus
- ® insulin glargine in patients with type 1 diabetes mellitus or type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18: 159-168.
- (2016) Diabetes Obes Metab , vol.18 , pp. 159-168
- Ilag, L.L.¹ Deeg, M.A.² Costigan, T.³

12
- 84959926174
- Food and Drug Administration. Guidance for industry assay development for immunogenicity testing of therapeutic proteins. Draft guidance. . Available from URL:. Accessed 16 December 2014.
- Food and Drug Administration. Guidance for industry assay development for immunogenicity testing of therapeutic proteins. Draft guidance. 2009. Available from URL: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM192750.pdf. Accessed 16 December 2014.
- (2009)

13
- 34249297061
- Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy
- Pieber TR, Treichel HC, Hompesch B et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635-642.
- (2007) Diabet Med , vol.24 , pp. 635-642
- Pieber, T.R.¹ Treichel, H.C.² Hompesch, B.³

14
- 24744442762
- Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy
- Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005; 35: 536-542.
- (2005) Intern Med J , vol.35 , pp. 536-542
- Fulcher, G.R.¹ Gilbert, R.E.² Yue, D.K.³

15
- 84959932994
- Diabetes UK. Position statement on Biosimilar insulins. . Available from URL:. Accessed 25 June 2015.
- Diabetes UK. Position statement on Biosimilar insulins. 2013. Available from URL: https://www.diabetes.org.uk/Documents/Position%20statements/diabetes-uk-position-statement-biosimilar-insulins-1013.pdf. Accessed 25 June 2015.
- (2013)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.